Search results
Results from the Health.Zone Content Network
PSC develops slowly. You may have it for years before you notice any symptoms. Some of the signs are: Fatigue. Itchy skin. Yellowish skin and eyes caused by a condition called jaundice. As PSC ...
Takeaway. Primary sclerosing cholangitis (PSC) is a rare liver disease that affects the bile ducts. PSC is progressive, which means it gets worse over time. Treatment includes taking certain ...
blurry vision. light sensitivity. double vision. glare in bright lights. seeing halos around lights. People with posterior subcapsular cataracts most often complain of glare in bright lights and ...
Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder characterized by inflammation and scarring of the bile ducts, which normally allow bile to drain from the gallbladder. Affected individuals may have no symptoms or may experience signs and symptoms of liver disease, such as yellow discoloration ...
Summary. Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, and primary sclerosing cholangitis (PSC) both involve the breakdown of your bile ducts. Both conditions are ...
Secondary sclerosing cholangitis (SSC) is a chronic cholestatic liver disease. SSC is a sclerosing cholangitis with a known cause. Alternatively, if no cause can be identified, then primary sclerosing cholangitis is diagnosed. SSC is an aggressive and rare disease with complex and multiple causes. It is characterized by inflammation, fibrosis ...
Diabetic snowflake cataracts are subtypes of cortical or PSC cataracts caused by diabetes. The “snowflake” refers to the small white dots that can form along the eye lens. Overall, this type ...
Male. Female. Continue. NEW: This symptom checker now includes the ability to select symptoms by body location. We hope this makes it easier for you to identify your symptoms and possible conditions. The tool also allows you to select multiple symptoms quickly. Click to see FAQs and tips for searching. Tell Us What You Think.